Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES)

Circulation

Volumn 133, Issue 11, 2016, Pages 1067-1072

  De Ferranti, Sarah D ^a   Rodday, Angie Mae ^b   Mendelson, Michael M ^a,c   Wong, John B ^b   Leslie, Laurel K ^b   Sheldrick, R Christopher ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Epidemiology; Hyperlipoproteinemia, type II; Risk factors

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLACK PERSON; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; ETHNICITY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FEMALE; HEALTH SURVEY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICAN AMERICAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; RACE; SENSITIVITY ANALYSIS; UNITED STATES; ADOLESCENT; AGE; AGED; BLOOD; CHILD; COMORBIDITY; ETHNIC GROUP; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; NUTRITION; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CHILD; COMORBIDITY; ETHNIC GROUPS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; NUTRITION SURVEYS; OBESITY; PREVALENCE; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84961851444     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018791     Document Type: Article

References (21)

1. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolae-mia: a prospective registry study. Eur Heart J. 2008;29:2625-2633. doi: 10.1093/eurheartj/ehn422.
2. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Effcacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
3. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercho-lesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160:421-429. doi: 10.1093/aje/kwh237.
4. Watts GF, Shaw JE, Pang J, Magliano DJ, Jennings GL, Carrington MJ. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol. 2015;185:69-71. doi: 10.1016/j. ijcard.2015.03.027.
5. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-390a. doi: 10.1093/eurheartj/eht273.
6. Shi Z, Yuan B, Zhao D, Taylor AW, Lin J, Watts GF. Familial hypercholes-terolemia in China: prevalence and evidence of underdetection and under-treatment in a community population. Int J Cardiol. 2014;174:834-836. doi: 10.1016/j.ijcard.2014.04.165.
7. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hyper-cholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956-3964. doi: 10.1210/jc.2012-1563.
8. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm. Accessed October 4, 2014.
9. Centers for Disease Control and Prevention. Division of Nutrition, Physical Activity, and Obesity Web site. http://www.cdc.gov/healthy-weight/assessing/index.html. Accessed October 4, 2014.
10. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA. 2012;308:1545-1554. doi: 10.1001/jama.2012.13260.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. World Health Organization. Familial hypercholesterolemia: report of a second WHO Consultation. Geneva, Switzerland: World Health Organization; 1999. WHO publication No. WHO/HGN/FH/CONS/99.2.
13. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifcations of multiple imputation theory. Prev Sci. 2007;8:206-213. doi: 10.1007/s11121-007-0070-9.
14. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specifc meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract. 2003;4:18. doi: 10.1186/1471-2296-4-18.
15. Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, Curtin LR. National Health and Nutrition Examination Survey: analytic guidelines, 1999-2010. Vital Health Stat 2. 2013:1-24.
16. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A; Cholesterol Treatment Trialists' (CTT) Collaboration. Effcacy and safety of LDL-lowering therapy among men and women: meta-anal-ysis of individual data from 174, 000 participants in 27 randomised trials. Lancet. 2015;385:1397-1405. doi: 10.1016/S0140-6736(14)61368-4.
17. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlip-idemia. J Clin Invest. 1973;52:1544-1568. doi: 10.1172/JCI107332.
18. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128(suppl 5):S213-S256.
19. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercholes-terolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171-176.
20. Risk of fatal coronary heart disease in familial hypercholesterolaemia: Scientifc Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991;303:893-896.
21. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration. Effcacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. doi: 10.1016/S0140-6736(10)61350-5.